Coherus Biosciences | CHRS - Selling And Administration Expenses


Coherus Biosciences reported $15M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
AbbVie USD 3.63B 54M Jun/2026
Acadia Pharmaceuticals USD 148.57M 12.22M Jun/2026
Akebia Therapeutics USD 23.53M 3.19M Dec/2025
ALKERMES USD 196.64M 67.96M Jun/2026
Alnylam Pharmaceuticals USD 347.92M 65.41M Jun/2026
Amarin USD 18.97M 1.03M Dec/2025
Amgen USD 1.72B 134M Jun/2026
Baxter International USD 735M 7M Jun/2026
Biogen USD 709.7M 155.4M Jun/2026
BioMarin Pharmaceutical USD 395.55M 137.27M Jun/2026
Bristol-Myers Squibb USD 1.83B 209M Jun/2026
Coherus Biosciences USD 15M 6.26M Dec/2025
Eli Lilly USD 3.43B 496M Jun/2026
Fujifilm JPY 236.14B 20.3B Mar/2026
Gilead Sciences USD 1.52B 70M Jun/2026
Ironwood Pharmaceuticals USD 33.33M 2.78M Dec/2024
Merck USD 2.89B 219M Jun/2026
Myriad Genetics USD 122.3M 6.7M Dec/2025
Pacira USD 91.81M 7.93M Jun/2026
Perrigo USD 3.28B 3.02B Jun/2026
Pfizer USD 3.41B 496M Jun/2026
PTC Therapeutics USD 73.89M 13.31M Mar/2026
Regeneron Pharmaceuticals USD 662.1M 14.4M Jun/2026
Sarepta Therapeutics USD 107.6M 53.57M Jun/2026
Teva Pharmaceutical Industries USD 1.03B 34M Jun/2026
Vertex Pharmaceuticals USD 582.2M 88.5M Jun/2026
Xencor USD 77.54M 4.59M Jun/2026
Zoetis USD 592M 4M Jun/2026